In silico Identification of Hypoxic Signature followed by reverse transcription-quantitative PCR Validation in Cancer Cell Lines
RNAseq
Hypoxia
MicroRNA
Journal
Iranian biomedical journal
ISSN: 2008-823X
Titre abrégé: Iran Biomed J
Pays: Iran
ID NLM: 9814853
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
aheadofprint:
12
12
2022
entrez:
10
1
2023
pubmed:
11
1
2023
medline:
2
2
2023
Statut:
epublish
Résumé
Hypoxic tumor microenvironment is one of the important impediments for conventional cancer therapy. This study aimed to computationally identify hypoxia-related messenger RNA (mRNA) signatures in nine hypoxic-conditioned cancer cell lines and investigate their role during hypoxia. Nine RNA sequencing (RNA-Seq) expression data sets were retrieved from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were identified in each cancer cell line. Then 23 common DEGs were selected by comparing the gene lists across the nine cancer cell lines. Reverse transcription-quantitative PCR (qRT-PCR) was performed to validate the identified DEGs. By comparing the data sets, GAPDH, LRP1, ALDOA, EFEMP2, PLOD2, CA9, EGLN3, HK, PDK1, KDM3A, UBC, and P4HA1 were identified as hub genes. In addition, miR-335-5p, miR-122-5p, miR-6807-5p, miR-1915-3p, miR-6764-5p, miR-92-3p, miR-23b-3p, miR-615-3p, miR-124-3p, miR-484, and miR-455-3p were determined as common micro RNAs. Four DEGs were selected for mRNA expression validation in cancer cells under normoxic and hypoxic conditions with qRT-PCR. The results also showed that the expression levels determined by qRT-PCR were consistent with RNA-Seq data. The identified protein-protein interaction network of common DEGs could serve as potential hypoxia biomarkers and might be helpful for improving therapeutic strategies.
Sections du résumé
Background
Hypoxic tumor microenvironment is one of the important impediments for conventional cancer therapy. This study aimed to computationally identify hypoxia-related messenger RNA (mRNA) signatures in nine hypoxic-conditioned cancer cell lines and investigate their role during hypoxia.
Methods
Nine RNA sequencing (RNA-Seq) expression data sets were retrieved from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were identified in each cancer cell line. Then 23 common DEGs were selected by comparing the gene lists across the nine cancer cell lines. Reverse transcription-quantitative PCR (qRT-PCR) was performed to validate the identified DEGs.
Results
By comparing the data sets, GAPDH, LRP1, ALDOA, EFEMP2, PLOD2, CA9, EGLN3, HK, PDK1, KDM3A, UBC, and P4HA1 were identified as hub genes. In addition, miR-335-5p, miR-122-5p, miR-6807-5p, miR-1915-3p, miR-6764-5p, miR-92-3p, miR-23b-3p, miR-615-3p, miR-124-3p, miR-484, and miR-455-3p were determined as common micro RNAs. Four DEGs were selected for mRNA expression validation in cancer cells under normoxic and hypoxic conditions with qRT-PCR. The results also showed that the expression levels determined by qRT-PCR were consistent with RNA-Seq data.
Conclusion
The identified protein-protein interaction network of common DEGs could serve as potential hypoxia biomarkers and might be helpful for improving therapeutic strategies.
Identifiants
pubmed: 36624663
doi: 10.52547/ibj.3803
pmc: PMC9971715
doi:
Substances chimiques
MicroRNAs
0
RNA, Messenger
0
KDM3A protein, human
EC 1.14.11.-
Jumonji Domain-Containing Histone Demethylases
EC 1.14.11.-
MIRN455 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-33Références
Oncol Lett. 2020 Jan;19(1):992-1000
pubmed: 31897212
Oncogene. 2011 Feb 17;30(7):876-82
pubmed: 21042279
J Mol Biol. 2009 Dec 11;394(4):789-803
pubmed: 19800890
G3 (Bethesda). 2014 Sep 05;4(11):2159-65
pubmed: 25193495
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Clin Transl Imaging. 2017;5(3):225-253
pubmed: 28596947
Oncol Lett. 2017 Jul;14(1):743-750
pubmed: 28693229
Int J Oncol. 2019 Jun;54(6):1981-1994
pubmed: 31081063
Cancer Cell Int. 2022 Apr 27;22(1):164
pubmed: 35477503
Oncotarget. 2017 Mar 21;8(12):19455-19466
pubmed: 28038450
Oncol Rep. 2017 Apr;37(4):2449-2458
pubmed: 28350134
Iran J Pharm Res. 2020 Fall;19(4):121-134
pubmed: 33841528
Biomed Res Int. 2015;2015:125094
pubmed: 25874201
Bioinformatics. 2009 Jan 15;25(2):288-9
pubmed: 19033274
Mol Med Rep. 2016 Aug;14(2):1765-70
pubmed: 27356628
Int J Mol Sci. 2020 Jun 16;21(12):
pubmed: 32560271
Cancers (Basel). 2021 Mar 20;13(6):
pubmed: 33804802
Onco Targets Ther. 2016 Jul 26;9:4569-81
pubmed: 27555782
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
Cardiovasc Res. 2012 Jun 1;94(3):469-79
pubmed: 22454363
Oncol Lett. 2017 Aug;14(2):1519-1525
pubmed: 28789374
Cancers (Basel). 2019 Aug 01;11(8):
pubmed: 31374935
Front Oncol. 2020 May 22;10:681
pubmed: 32528874
Mol Cell Biol. 2007 Mar;27(5):1859-67
pubmed: 17194750
PLoS Genet. 2006 Jun 2;2(6):e88
pubmed: 16751849
Oncotarget. 2016 Oct 26;7(46):74526-74536
pubmed: 27793029
BMC Cancer. 2019 Jun 28;19(1):642
pubmed: 31253120
Nucleic Acids Res. 2013 Jan;41(Database issue):D377-86
pubmed: 23193289
Cancer Lett. 2017 Sep 10;403:28-36
pubmed: 28610954
RNA. 2006 Feb;12(2):192-7
pubmed: 16373484
Nat Protoc. 2015 Jun;10(6):823-44
pubmed: 25950236
Clin Epigenetics. 2019 Feb 11;11(1):25
pubmed: 30744689
Mol Med Rep. 2020 Aug;22(2):1155-1168
pubmed: 32468072
World J Biol Chem. 2017 Feb 26;8(1):45-56
pubmed: 28289518
Mol Cancer. 2019 Nov 11;18(1):157
pubmed: 31711497
Oncogene. 2016 Jun 23;35(25):3314-23
pubmed: 26455327
Cells. 2020 Jun 27;9(7):
pubmed: 32605009
Nucleic Acids Res. 2011 Jan;39(Database issue):D163-9
pubmed: 21071411
Biosci Rep. 2019 May 15;39(5):
pubmed: 31036603
Biochem Cell Biol. 2020 Jun;98(3):386-395
pubmed: 31742425
Oncogenesis. 2020 Feb 18;9(2):24
pubmed: 32071289
Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4
pubmed: 18077471
Bioinformatics. 2017 Sep 15;33(18):2938-2940
pubmed: 28645171
Cell Metab. 2006 Mar;3(3):177-85
pubmed: 16517405
Cancer Sci. 2020 Aug;111(8):3071-3081
pubmed: 32530543
Sci Rep. 2019 Mar 21;9(1):4980
pubmed: 30899073
Cell Death Differ. 2013 Aug;20(8):1043-54
pubmed: 23645209
Leukemia. 2015 May;29(5):1163-76
pubmed: 25394713
Oncol Lett. 2018 Feb;15(2):1680-1690
pubmed: 29434863
J Clin Endocrinol Metab. 2019 May 21;:
pubmed: 31112271
Int J Mol Sci. 2020 Nov 20;21(22):
pubmed: 33233641
Front Immunol. 2017 Nov 22;8:1549
pubmed: 29213268